Clinical trials will test if antibodies against the coronavirus prevent infection, aid survival
A patient in Beijing who has recovered from COVID-19 donates plasma, the liquid part of blood, which contains antibodies against the coronavirus.
Since March 28, at least 11 patients critically ill with COVID-19 at hospitals in New York City and Houston became the first in the United States to receive a promising experimental treatment. But the therapy, newly authorized for emergency use by the U.S. Food and Drug Administration, wasn’t concocted in a pharmaceutical laboratory. It came from the blood of other patients, those who have recovered from the coronavirus infection.
The treatment is convalescent plasma, the liquid component of blood taken from someone who has survived an infection, in this case COVID-19. With the United States now leading the world in confirmed cases of the disease — and no proven treatments yet — researchers here are racing to set up clinical trials to test how effective convalescent plasma is against SARS-CoV-2, the virus that causes COVID-19. If the treatment is beneficial, that could lead to FDA approval for wider use.
A vaccine against SARS-CoV-2 is at best more than year away (SN: 2/21/20). In trying to manage COVID-19 over the next several months, the question is, “what kind of treatments could we administer that could truncate this pandemic?” says pathologist John Roback of Emory University School of Medicine in Atlanta, who does research on transfusion medicine. The top candidates are drugs already approved to treat diseases such as malaria that might be repurposed for COVID-19 (SN: 3/10/20) and convalescent plasma, he says.
To fight a virus, the immune system develops antibodies, proteins that bind to parts of the virus and impede the infection. When a person makes antibodies in response to an infection or upon getting a vaccine, it’s called active immunity. The initial ramp up to antibody production can take about a week or two, but once that has occurred, the immune system will be able to quickly respond to the next exposure to the virus. For some viruses and vaccines, active immunity can last decades or even lifelong.
Convalescent plasma, also called passive antibody therapy, is a type of passive immunity. It can provide antibodies immediately, but the proteins will last only for a short amount of time, weeks to possibly a few months.
“We’re using the antibody-rich plasma from the convalescent patient … to prevent infection or treat infection in another patient,” says Jeffrey Henderson, an infectious disease physician and scientist at Washington University School of Medicine in St. Louis.
Setting up clinical trials
Henderson is part of a group of U.S. researchers working to set up clinical trials for convalescent plasma, called the National COVID-19 Convalescent Plasma Project. There are plans to test the plasma in three different groups.
One randomized clinical trial is designed to investigate whether plasma can prevent infection in people exposed to COVID-19 by a close contact, such as a family member, says project member Shmuel Shoham, an infectious disease physician at Johns Hopkins University School of Medicine. The trial will test plasma from recovered COVID-19 patients against a placebo — plasma taken from patients prior to the December 2019 start of the epidemic, he says.
Another trial is planned to test whether plasma can keep people with moderate disease who are in the hospital from needing intensive care, Shoham says. And a third trial aims to study whether the therapy helps the most critically ill patients. The project is waiting on a green light from the FDA to start enrolling patients in all of the trials.
Controlled clinical trials are necessary to get definitive answers on whether convalescent plasma can stop disease or improve symptoms of COVID-19, and which people it could help the most. But a look at the history of infectious diseases, described in a commentary April 1 in the Journal of Clinical Investigation, provides many instances in which passive antibody therapy appeared to prevent or ameliorate infections. Convalescent plasma was used to help stop outbreaks of measles and mumps before vaccines were available, and there’s some evidence that those who got the plasma during the 1918 influenza pandemic were less likely to die.
Convalescent plasma has also been put to use against SARS and MERS, the two other coronavirus epidemics. But studies that showed some benefit didn’t compare how the treatment worked against a placebo. That’s also true for the first studies on using the plasma to treat COVID-19. In one, five patients critically ill with COVID-19 and on mechanical ventilation received convalescent plasma 10 to 22 days after being admitted to a hospital in Shenzhen, China. As of March 25, three of the patients had been discharged, after a little over 50 days in the hospital, and two were in stable condition 37 days after the transfusion, researchers report March 27 in JAMA. Although the patients improved, they had also gotten antiviral medications, so it’s unclear which therapy, if any, had an impact.
In the United States, some blood banks and hospitals are gearing up to collect plasma from people who’ve recovered from COVID-19. The Red Cross has set up a donor request form for people who would like to contribute plasma. The National COVID-19 Convalescent Plasma Project also has information on how to register to donate plasma.
For the U.S. clinical trials, the researchers will be scrutinizing the donated plasma to determine whether it contains neutralizing antibodies, Henderson says. This type of antibody prevents the virus from entering a host cell, thereby stopping the infection. Data so far suggest that the spike protein, a particular protein in SARS-CoV-2 which the virus uses to bind to a protein on human cells (SN: 2/3/20), is a target of neutralizing antibody.
Researchers suspect that this type of antibody is what makes convalescent plasma effective. And it also hints at when using the plasma may be most beneficial.
Early on in the disease, the virus is infecting cells and hijacking cell machinery to make many copies of itself. “But as the disease progresses, the tissue damage done by the virus is more difficult to reverse and isn’t necessarily reversed by something that is solely targeted towards the virus itself,” such as antibodies, says Henderson. The body’s inflammatory response can be contributing to the damage.
It doesn’t mean that passive antibody therapy wouldn’t help someone critically ill with COVID-19, he says. “We have so much to learn, of course, but we’re thinking the antibodies may prevent the virus from expanding its numbers.”
Clinical trials of convalescent plasma are beginning in other countries, too. As doctors await answers from completed trials, additional patients may receive the treatment under the FDA’s emergency authorization. It’s great that critically ill patients and their doctors have that option, Shoham says. In the meantime, “we’re trying to … find out if [convalescent plasma] actually works.
A. Casadevall and L.-A. Pirofski. The convalescent sera option for containing COVID-19. Journal of Clinical Investigation. Vol. 130, April 1, 2020, p. 1545. doi: 10.1172/JCI138003
C. Shen et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. Published online March 27, 2020. doi:10.1001/jama.2020.4783
Labels: Covid-19, COVID-19 treatments, COVID-19 tests, Coronavirus Cases in India, Coronavirus Latest updates, Coronavirus News, COVID-19 trials, Coronavirus treatments, COVID-19 treatments, COVID-19 clinical trials, coronavirus ongoing trials, Coronavirus breaking news, Coronavirus updates, Coronavirus new cases, coronavirus outbreak, COVID-19 coronavirus